Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lisata Therapeutics Inc LSTA

Healthcare Biotechnology
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.


NDAQ:LSTA - Post by User

Lisata Therapeutics Inc
Bullboard Posts
Next >>
User Avatar Image
(29)
•••
Post by HugeMoneyon Sep 01, 2020 2:40pm
121 Views
Post# 31487800

News Out - Good Company

News Out - Good Company

LD Micro 360 Companies Set to Present this Week

BTN, T.BLU, BMRA, CVM, CLRO, CMPSP, CTG, DRAD, DGLY, CELH, CTEK, CTXR, CAPR, CLBS, CETX, BKYI, CLXT, C.CALI, DPW, CLSK, DCTH, CANB, BLCT | 21 hours ago

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

Registration details and the company schedule can be seen here: https://ld500.ldmicro.com

"I have slept well since March," said Chris Lahiji, Founder of LD Micro.

The list of presenters in below:


Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities